MUC5AC expression as a predictive biomarker of omental metastasis in primary mucinous ovarian carcinoma

Desy Ekamadayani Ahmad; Rina Masadah; Berti Julian Nelwan; Upik Anderiani Miskad; Djumadi Achmad; Amalia Yamin; Suryani Tawali

doi:10.23750/abm.v96i5.17657

MUC5AC expression as a predictive biomarker of omental metastasis in primary mucinous ovarian carcinoma

Authors

Desy Ekamadayani Ahmad Department of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia https://orcid.org/0009-0005-3491-8359
Rina Masadah Department of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia https://orcid.org/0000-0002-1380-4759
Berti Julian Nelwan Department of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia https://orcid.org/0000-0002-1999-2412
Upik Anderiani Miskad Department of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia; Anatomical Pathology Laboratory, Hasanuddin University Hospital, Makassar, Indonesia https://orcid.org/0000-0002-1980-395X
Djumadi Achmad Department of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia https://orcid.org/0000-0003-4060-6827
Amalia Yamin Department of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia; Anatomical Pathology Laboratory, Wahidin Sudirohusodo Hospital, Makassar, Indonesia https://orcid.org/0009-0008-5383-3408
Suryani Tawali Department of Public Health, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia https://orcid.org/0000-0002-2008-469X

Keywords:

MUC5AC expression, mucinous ovarian carcinoma, omental metastasis, predictive biomarker

Abstract

Background and aim: Primary mucinous ovarian carcinoma is an uncommon epithelial ovarian cancer subtype with poor advanced prognosis. Identifying predictive biomarker of early metastatic spread is essential for improving staging and therapeutic strategies. Mucin 5AC (MUC5AC), a secretory glycoprotein, has been linked to tumor progression and epithelial–mesenchymal transition (EMT). This study aimed to evaluate the association between MUC5AC expression and omental metastasis in primary mucinous ovarian carcinoma.

Methods: A cross-sectional study was conducted to semi-quantitatively analyze MUC5AC expression in 63 paraffin-embedded tissue samples of primary mucinous ovarian carcinoma. Immunohistochemical staining was performed using a rabbit polyclonal MUC5AC antibody. Expression levels were categorized as low or high based on intensity and distribution. A Chi-square test was used to assess the relationship between MUC5AC expression and omental metastasis.

Results: The study included 63 cases of primary mucinous ovarian carcinoma, consisting of 37 (58.7%) with omental metastasis and 26 (41.3%) without metastasis. High MUC5AC expression was observed in 86.5% of metastatic cases and in 50.0% of non-metastatic cases. This difference was statistically significant (P-value 0.002 [≤0.05]). Patients with high MUC5AC expression had a 6.40 times higher likelihood of omental metastasis than those with low expression (95% CI: 1.89–21.5).

Conclusions: High MUC5AC expression was significantly associated with omental metastasis in primary mucinous ovarian carcinoma, supporting its potential role as a predictive biomarker for metastatic risk stratification. (www.actabiomedica.it)

References

1. Wang Y, Liu L, Yu Y. Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment. Heliyon. 2023;9(8):e19221. doi: 10.1016/j.heliyon.2023.e19221.

2. Globocan Observatory WHO. Ovarian Cancer Incidence and Mortality. Int Agency Res Cancer GLOBOCAN. 2020;5–6. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf.

3. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Int J Womens Health. 2019;11:287–99. doi: 10.2147/IJWH.S197604.

4. Morice P, Gouy S, Leary A. Mucinous Ovarian Carcinoma. N Engl J Med. 2019;380(13):1256–66. doi: 10.1056/nejmra1813254.

5. Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol. 2017;29(1):26–34. doi: 10.1097/GCO.0000000000000340.

6. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. J Turkish-German Gynecol Assoc. 2019;20(1):47–54. doi: 10.4274/jtgga.galenos.2018.2018.0119.

7. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: Type I and type II. Biomed Res Int. 2014;2014. doi: 10.1155/2014/934261.

8. Javadi S, Ganeshan DM, Qayyum A, Iyer RB, Bhosale P. Ovarian cancer, the revised FIGO staging system, and the role of imaging. Am J Roentgenol. 2016;206(6):1351–60. doi: 10.2214/AJR.15.15199.

9. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053–64. doi: 10.2353/ajpath.2010.100105.

10. Yang Y, Yang Y, Yang J, Zhao X, Wei X. Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. Front Cell Dev Biol. 2020;8(August):1–30. doi: 10.3389/fcell.2020.00758.

11. Rico SD, Mahnken M, Buscheck F, Dum D, Luebke AM, Kluth M. MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue - A Tissue Microarray Study on 10 399 Tissue Samples. Technol Cancer Res Treat. 2021;20:1–13. doi: 10.1177/15330338211043328.

12. Kufe DW. Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer. 2009;9(12):874–85. doi: 10.1038/nrc2761.

13. Kelemen LE, Köbel M. Mucinous carcinomas of the ovary and colorectum: Different organ, same dilemma. Lancet Oncol. 2011;12(11):1071–80. doi: 10.1016/S1470-2045(11)70058-4.

14. Chelariu-Raicu A, Holley E, Mayr D, et al. A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary. Int J Gynecol Cancer. 2022;662–8. doi: 10.1136/ijgc-2021-003104.

15. Jun SY, Lee EJ, Kim S Il, An S. Tumor Microenvironment Prognostic Risk and Its Association with MUC5AC in Ampullary Carcinoma. Arch Pathol Lab Med. 2023;147(9):1060–74. doi: 10.5858/arpa.2022-0131-OA.

16. Rico SD, Schmalfeldt B, Müller V, et al. MUC5AC expression is linked to mucinous/endometroid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer. Pathol Res Pract. 2021;224(January). doi: 10.1016/j.prp.2021.153533.

17. Krishn SR, Ganguly K, Kaur S, Batra SK. Ramifications of secreted mucin MUC5AC in malignant journey: A holistic view. Carcinogenesis. 2018;39(5):633–51. doi: 10.1093/carcin/bgy019.

18. Marimuthu S, Rauth S, Ganguly K, et al. Mucins reprogram stemness, metabolism and promote chemoresistance during cancer progression. Cancer Metastasis Rev. 2021;40(2):575–88. doi: 10.1007/s10555-021-09959-1.

19. Reynolds IS, Fichtner M, McNamara DA, Kay EW, Prehn JHM, Burke JP. Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers. Cancer Metastasis Rev. 2019;38(1–2):237–57. doi: 10.1007/s10555-019-09781-w.

20. Pothuraju R, Rachagani S, Krishn SR, et al. Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance. Mol Cancer. 2020;19(1):1–14. doi: 10.1186/s12943-020-01156-y.

21. Ganguly K, Krishn SR, Rachagani S, et al. Secretory Mucin 5AC Promotes Neoplastic Progression by Augmenting KLF4-Mediated Pancreatic Cancer Cell Stemness. Cancer Res. 2021;81(1):91–102. doi: 10.1158/0008-5472.CAN-20-1293.